Logo

Merck KGaA

Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics

The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.

Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium

Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance. 

Sigma-Aldrich Licenses CRISPR-Cas9 Tech to Horizon Discovery

The deal enables Horizon to support gene editing researchers who need cell-line engineering beyond loss-of-function CRISPR studies into CRISPR-mediated targeted knock-in.

Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal

The companies intend to develop Burning Rock's 168-gene OncoCompass Target test as a companion to Merck's MET inhibitor Tepmetko in mainland China.

Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko

The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.

Dec 23, 2020

Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China

Aug 20, 2020

AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug

Aug 3, 2020

Metabolon, Merck KGaA Form Metabolomics Alliance

Mar 25, 2020

Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx

Nov 19, 2019

Personalis, Merck KGaA to Study Cancer Biomarkers Using Immunogenomics Platform

Sep 23, 2019

Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
Premium

Oct 3, 2018

Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic

Sep 10, 2018

Definiens, Merck KGaA Partner for Biomarker Discovery

Jun 20, 2018

Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations
Premium

Jan 10, 2018

ThermaGenix, MilliporeSigma Ink PCR Reagents Distribution Deal

Dec 27, 2017

HTG Expands Collaboration With Merck KGaA

Nov 27, 2017

Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests

Sep 26, 2017

FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug

Jun 15, 2017

Human Longevity, Merck KGaA Form Cancer Biomarker Partnership

Jun 13, 2017

MilliporeSigma's Proxy-CRISPR Tech Aims to Increase Usability of Native CRISPR Proteins
Premium

May 30, 2017

Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest
Premium

Apr 11, 2017

MilliporeSigma Developing New Instrument for Single-Molecule Biomarker Detection
Premium

Jan 6, 2017

Guardant Health, Pharma Firms to Develop 500-Gene Liquid Biopsy Panel

Dec 1, 2016

Roche, Merck KGaA Expand PCR Distribution Agreement

Nov 30, 2016

Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.